Business Parks & Science Centres

 
 
 

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Organisation › Details

Hookipa (Group)

HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, VaxWave® and TheraT®, are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system. HOOKIPA has successfully completed a Phase 1 trial of a VaxWave®-based prophylactic vaccine to protect against cytomegalovirus infection and has started dosing patients in a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, selfantigens and next-generation antigens. *

 

Period Start 2011-07-01 established
Products Industry Vaxwave® technology
  Industry 2 HB-101 (Hookipa)
Persons Person Aldag, Jörn (Hookipa Biotech 201606– CEO before Uniqure/AMT + Evotec + MAN GHH)
  Person 2 Mummenbrauer, Torsten (Hookipa 201610–201904 SVP Bus Dev + Licensing before MorphoSys + GSK Vaccines LEFT 5/19)
     
Region Region Wien (Vienna)
  Country Austria
  Street 2 Helmut-Qualtinger-Gasse
  City 1030 Wien
  Tel +43-1-890-6360
    Address record changed: 2018-09-13
     
Basic data Employees C: 51 to 100 (2019-02-28)
  Currency USD
  Annual sales 7,629,000 (revenues, consolidated (2018) 2018-12-31)
  Profit -16,237,000 (2018-12-31)
  Cash 48,580,000 (2018-12-31)
     
    * Document for �About Section�: Hookipa Pharma Inc.. (2/26/19). "Press Release: Hookipa Pharma Raises $37.4 Million (€33.2 Million) in Series D Financing". New York, NY & Vienna.
     
   
Record changed: 2019-04-21

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

More documents for Hookipa (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px




» top